Stanford is enrolling participants in a study that looks at how safe a potential new drug is, and whether it works for people with schizophrenia when given with existing antipsychotic medications.
This is a new medication, Cobenfy , that was recently approved by the FDA.
You, or someone you care for, may be able to take part in the study.
To participate you must be:
- between 18 and 65 years of age
- have schizophrenia
- already take antipsychotic medications, but still have symptoms.
Research commitment:
- be in the study for up to 13 weeks
- visit the study center for up to 9 times
- continue to take your current antipsychotic medications as instructed
The study has been reviewed by an Institutional Review Board (IRB)/Ethics Committee (EC).
See the research flyer here.
For addition information click here or contact Daniel Virtheim at dmvirt@standford.edu or 650.353.7030.
